Short Squeeze Mania.
Citius Pharma (CTXR) Locked and Loaded.
Truly Locked and Loaded. Latest $20 Million Round is Biggest News We've Seen...
Newsletter: Institutional Analyst. And Yes, We Have Another Double.
1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....
Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.
The 2021 Biotech Six Pack, Six Stocks We Expect to Double.
We're still putting the 2021 list together now,...
And We Have Our First MEME Stock! $2.00 to $29.95.
Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg)
Guess we were bound to stumble across...
Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
Starts at 1 Hour Mark.
INSIDER HOLDINGS
Citius (CTXR) Announces Results of Mino-Lok Study.
"Mino-Lok has the potential to change the standard of care, which currently calls for a procedure to remove and replace the infected...
Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).
Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal.
We've had...
Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).
Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR)
Summary
Lantern Pharma (LTRN) $21.25 and Provention Bio (PRVB) $13.51 Added to Biotech Six Pack.
The 2021 Biotech Six Pack: Stocks We Expect to Double!
These are ideas #3 and #4 for the 'Biotech...
American BriVision (ABVC) Reports Completion Clinical Trial for Treatment of Adult ADHD.
American BriVision (ABVC) Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD.
Last...